Meeting Banner
Abstract #1785

Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness

Guro F. Giskedegrd1, 2, Helena Bertilsson3, 4, Kirsten M. Selns1, 2, Alan Wright5, Tone Frost Bathen1, 2, Trond Viset6, Jostein Halgunset3, 6, Anders Angelsen4, Ingrid Susann Gribbestad1, 2, May-Britt Tessem1, 2

1Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; 2St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; 3Department of Laboratory Medicine and Children's and Women's Helath, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; 5Department of Radiology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 6Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway


Metabolite profiles of human prostate and normal adjacent tissue obtained with high resolution magic angle spinning (HR-MAS) MRS can be used to identify metabolic biomarkers for prostate cancer aggressiveness. Multivariate analysis of metabolite profiles and absolute quantification of individual metabolites were used to examine the metabolic changes and predict cancer aggressiveness. The detailed metabolite profiles distinguished cancer and normal adjacent tissues and the profiles were related to prostate cancer aggressiveness. Spermine and citrate are proposed as biomarkers for separating indolent from aggressive prostate cancers.